METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2025

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Nivolumab

"FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks."

DRUG

FLOX

FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.

Trial Locations (5)

1478

Akershus University Hospital, Oslo

4604

Hospital of Southern Norway, Department of Oncology, Kristiansand

5021

Haukeland University Hospital, Bergen

7006

St Olav's Hospital - Trondheim University Hospital, Trondheim

0424

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Trondheim University Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Hospital of Southern Norway Trust

OTHER

collaborator

Oslo University Hospital

OTHER

lead

University Hospital, Akershus

OTHER

NCT03388190 - METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin | Biotech Hunter | Biotech Hunter